OTC$LIANY
Lianbio-Adr · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
LianBio reported financial results for the first quarter ended March 31, 2023.
LianBio reported a net loss of $24.0 million for the first quarter of 2023, compared to a net loss of $27.7 million for the first quarter of 2022. The company's cash, cash equivalents, marketable securities and restricted cash totaled $286.6 million as of March 31, 2023, and is projected to fund operations through the end of 2024. The company is preparing for the commercial launch of mavacamten in China.
- Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpoint.
- China National Medical Products Administration (NMPA) accepted mavacamten New Drug Application (NDA) with priority review.
- Mavacamten commercial launch preparations continue in China, supported by the promotion of Pascal Qian to Chief Commercial Official.
- Cash, cash equivalents and marketable securities of $286.5 million with runway through the end of 2024.
Headline financials
Revenue & EPS history
Lianbio-Adr · Revenue · Quarterly
$0
Forward guidance
LianBio projects its current cash, cash equivalents, marketable securities, and restricted cash will be sufficient to fund its current operating plan through the end of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2023
+8.4%
Avg return
Earnings day
+8.4%
Avg return
5 days after
-3.1%
Avg return
30 days after
77%
10 / 13 earnings
Positive
+17.7%
Q4 2020
Best reaction
-4.1%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2024 | -2.2% | -6.7% | -7.4% | |
| Q3 2023 | +0.7% | +1.5% | +4.2% | |
| Q2 2023 | +2.7% | +0.0% | -9.7% | |
| Q1 2023 | -4.1% | +4.6% | +17.7% | |
| Q4 2022 | -1.2% | +17.4% | +18.0% | |
| Q3 2022 | +17.5% | +38.9% | +7.1% | |
| Q2 2022 | +11.1% | -1.5% | -3.0% | |
| Q1 2022 | +9.3% | +29.8% | +28.4% | |
| Q4 2021 | +3.9% | +26.1% | +7.3% | |
| Q2 2021 | +17.7% | +0.4% | -17.3% | |
| Q3 2021 | +17.7% | +0.4% | -17.3% | |
| Q4 2020 | +17.7% | +0.4% | -17.3% | |
| Q1 2021 | +17.7% | -2.4% | -50.4% | |
| Q3 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro